Assignee
GENMAB AS
DK·79 granted patents·148 pending applications·1,292 citations·filing 2002–2025
Top patents by PatentIndex Score
227 records- 0198US11485796B2Inert formatGENMAB AS·Filed 2020·Granted Nov 1, 2022·6 cites·20 claims
- 0298US11440966B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 13, 2022·12 cites·21 claims
- 0398US11084882B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2020·Granted Aug 10, 2021·8 cites·11 claims
- 0498US7829673B2Antibodies against CD38 for treatment of multiple myelomaGENMAB AS·Filed 2006·Granted Nov 9, 2010·148 cites·29 claims
- 0598US7247301B2Human monoclonal antibodies to epidermal growth factor receptor (EGFR)GENMAB AS·Filed 2002·Granted Jul 24, 2007·215 cites·24 claims
- 0698US7153507B2Human antibodies specific for interleukin 15 (IL-15)GENMAB AS·Filed 2002·Granted Dec 26, 2006·367 cites·32 claims
- 0797US11866514B2Heterodimeric antibody Fc-containing proteins and methods for production thereofGENMAB AS·Filed 2020·Granted Jan 9, 2024·5 cites·37 claims
- 0897US10597464B2Heterodimeric antibody Fc-containing proteins and methods for production thereofGENMAB AS·Filed 2017·Granted Mar 24, 2020·35 cites·12 claims
- 0996US11608383B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Mar 21, 2023·8 cites·30 claims
- 1096US11535679B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Dec 27, 2022·8 cites·27 claims
- 1196US11091557B2Methods of producing multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2017·Granted Aug 17, 2021·10 cites·20 claims
- 1296US10590206B2Inert formatGENMAB AS·Filed 2014·Granted Mar 17, 2020·29 cites·20 claims
- 1395US12077596B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 3, 2024·2 cites·20 claims
- 1495US11939388B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Mar 26, 2024·2 cites·13 claims
- 1595US11845805B2Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphomaGENMAB AS·Filed 2021·Granted Dec 19, 2023·5 cites·33 claims
- 1695US11548952B2Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphomaGENMAB AS·Filed 2021·Granted Jan 10, 2023·7 cites·27 claims
- 1795US10906991B2Bispecific antibodies and methods for production thereofGENMAB AS·Filed 2015·Granted Feb 2, 2021·15 cites·6 claims
- 1895US10344050B2Production of heterodimeric proteinsGENMAB AS·Filed 2012·Granted Jul 9, 2019·40 cites·52 claims
- 1994US10407501B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2015·Granted Sep 10, 2019·15 cites·19 claims
- 2094US7595378B2Human monoclonal antibodies to epidermal growth factor receptor (EGFR)GENMAB AS·Filed 2002·Granted Sep 29, 2009·64 cites·14 claims
- 2194US7438907B2Human monoclonal antibodies against CD25GENMAB AS·Filed 2003·Granted Oct 21, 2008·50 cites·31 claims
- 2293US11858995B2Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemiaGENMAB AS·Filed 2021·Granted Jan 2, 2024·4 cites·28 claims
- 2393US11492371B2Production of heterodimeric proteinsGENMAB AS·Filed 2019·Granted Nov 8, 2022·9 cites·21 claims
- 2493US10544220B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2016·Granted Jan 28, 2020·18 cites·12 claims
- 2593US9944711B2Antibodies against human CD38GENMAB AS·Filed 2016·Granted Apr 17, 2018·16 cites·48 claims
- 2693US9492565B2Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2015·Granted Nov 15, 2016·7 cites·16 claims
- 2793US7282568B2Human monoclonal antibodies against interleukin 8 (IL-8)GENMAB AS·Filed 2003·Granted Oct 16, 2007·39 cites·23 claims
- 2892US11613575B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2019·Granted Mar 28, 2023·4 cites·18 claims
- 2992US11359015B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2016·Granted Jun 14, 2022·6 cites·24 claims
- 3092US9657107B2Monoclonal antibodies against c-MetGENMAB AS·Filed 2015·Granted May 23, 2017·9 cites·25 claims
- 3191US11008399B2AntibodiesGENMAB AS·Filed 2020·Granted May 18, 2021·2 cites·22 claims
- 3291US7850962B2Human monoclonal antibodies against CD20GENMAB AS·Filed 2005·Granted Dec 14, 2010·27 cites·49 claims
- 3390US10201607B2Antibodies binding AXLGENMAB AS·Filed 2018·Granted Feb 12, 2019·7 cites·28 claims
- 3490US9714297B2Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2015·Granted Jul 25, 2017·9 cites·29 claims
- 3589US10765743B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Sep 8, 2020·3 cites·46 claims
- 3688US11130819B2AntibodiesGENMAB AS·Filed 2021·Granted Sep 28, 2021·1 cites·30 claims
- 3788US7622559B2Human monoclonal antibodies against interleukin 8 (IL-8)GENMAB AS·Filed 2007·Granted Nov 24, 2009·7 cites·15 claims
- 3887US10500276B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Dec 10, 2019·4 cites·35 claims
- 3986US11459395B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2021·Granted Oct 4, 2022·1 cites·19 claims
- 4086US10512688B2Antibodies binding AXLGENMAB AS·Filed 2015·Granted Dec 24, 2019·4 cites·8 claims
- 4186US2024294661A1Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2023·Application pending·0 cites
- 4286US2024209117A1Heterodimeric antibody fc-containing proteins and methods for production thereofGENMAB AS·Filed 2023·Application pending·0 cites
- 4385US11046771B2Monoclonal antibodies against HER2GENMAB AS·Filed 2017·Granted Jun 29, 2021·2 cites·23 claims
- 4485US7329405B2Human antibodies specific for interleukin 15 (IL-15)GENMAB AS·Filed 2003·Granted Feb 12, 2008·11 cites·10 claims
- 4585US7247304B2Methods of treating using anti-IL-15 antibodiesGENMAB AS·Filed 2003·Granted Jul 24, 2007·21 cites·18 claims
- 4685US2024392032A1AntibodiesGENMAB AS·Filed 2024·Application pending·0 cites
- 4784US12589150B2Antibodies binding AXLGENMAB AS·Filed 2023·Granted Mar 31, 2026·0 cites·21 claims
- 4884US9598493B2Human monoclonal antibodies against CD25GENMAB AS·Filed 2015·Granted Mar 21, 2017·3 cites·11 claims
- 4984US7585961B2Nucleic acid encoding human antibodies specific for interleukin 15 (IL-15)GENMAB AS·Filed 2007·Granted Sep 8, 2009·5 cites·22 claims
- 5084US2024228662A9Antibodies against cd38 for treatment of multiple myelomaGENMAB AS·Filed 2023·Application pending·0 cites
Showing the top 50 of 227 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →